BioWorld

May 16, 2006

View Archived Issues

AstraZeneca Buying CAT, Giving Valuation Of $1.3B

LONDON - AstraZeneca plc is buying Cambridge Antibody Technology (CAT) Group plc, the UK's largest biotech, in an agreed cash deal that will cost AstraZeneca £567 million, and values CAT at £702 million (US$1.3 billion). (BioWorld Today) Read More

Clinical Data Spins Off Precigen To Continue Phase III Research

Read More

Marshall Edwards Licenses Two Oncology Compounds

Read More

Congresswoman Calls For More FDA Power On Phase IV Studies

Read More

Clinic Roundup

Read More

U.S. Patent Disclosures

Read More

Other News To Note

Read More